Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9UNW1
UPID:
MINP1_HUMAN
Alternative names:
2,3-bisphosphoglycerate 3-phosphatase; Inositol (1,3,4,5)-tetrakisphosphate 3-phosphatase
Alternative UPACC:
Q9UNW1; F5H683; O95172; O95286; Q59EJ2; Q9UGA3
Background:
Multiple inositol polyphosphate phosphatase 1 (MIPP1) plays a pivotal role in cellular processes by regulating the levels of inositol pentakisphosphate (InsP5) and inositol hexakisphosphate (InsP6). It also functions as a 2,3-bisphosphoglycerate 3-phosphatase, influencing bone development and chondrocyte maturation. Its activity is crucial for maintaining intracellular cation homeostasis, including calcium and iron, essential for neural cell signaling.
Therapeutic significance:
MIPP1 is implicated in non-medullary thyroid cancer and pontocerebellar hypoplasia 16, diseases with significant genetic components. Understanding MIPP1's role could lead to novel therapeutic strategies targeting these conditions, potentially offering new avenues for treatment and management.